WallStreetZenWallStreetZen

NASDAQ: HOTH
Hoth Therapeutics Inc Stock

$1.30+0.00 (+0%)
Updated Feb 23, 2024
HOTH Price
$1.30
Fair Value Price
N/A
Market Cap
$5.63M
52 Week Low
$0.99
52 Week High
$4.30
P/E
-0.27x
P/B
0.54x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$9.62M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.15
Operating Cash Flow
-$8M
Beta
0.46
Next Earnings
Mar 31, 2024
Ex-Dividend
N/A
Next Dividend
N/A

HOTH Overview

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how HOTH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

HOTH is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HOTH is good value based on its book value relative to its share price (0.54x), compared to the US Biotechnology industry average (6.12x)
P/B vs Industry Valuation
HOTH is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more HOTH due diligence checks available for Premium users.

Be the first to know about important HOTH news, forecast changes, insider trades & much more!

HOTH News

Valuation

HOTH fair value

Fair Value of HOTH stock based on Discounted Cash Flow (DCF)
Price
$1.30
Fair Value
$6.56
Undervalued by
80.18%
HOTH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

HOTH price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.27x
Industry
16.16x
Market
33.56x

HOTH price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.54x
Industry
6.12x
HOTH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

HOTH's financial health

Profit margin

Revenue
$0.0
Net Income
-$2.1M
Profit Margin
0%
HOTH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$12.1M
Liabilities
$1.6M
Debt to equity
0.15
HOTH's short-term assets ($12.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HOTH's short-term assets ($12.05M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HOTH's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
HOTH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.6M
Investing
$0.0
Financing
$2.4M
HOTH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

HOTH vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
HOTH$5.63M0.00%-0.27x0.54x
CELZ$5.57M-4.05%-0.52x0.46x
IMNN$5.54M+4.06%-0.18x0.31x
MYMD$5.73M-3.70%-0.63x0.37x
ADXN$5.80M-9.36%-57.22x1.31x

Hoth Therapeutics Stock FAQ

What is Hoth Therapeutics's quote symbol?

(NASDAQ: HOTH) Hoth Therapeutics trades on the NASDAQ under the ticker symbol HOTH. Hoth Therapeutics stock quotes can also be displayed as NASDAQ: HOTH.

If you're new to stock investing, here's how to buy Hoth Therapeutics stock.

What is the 52 week high and low for Hoth Therapeutics (NASDAQ: HOTH)?

(NASDAQ: HOTH) Hoth Therapeutics's 52-week high was $4.30, and its 52-week low was $0.99. It is currently -69.88% from its 52-week high and 30.81% from its 52-week low.

How much is Hoth Therapeutics stock worth today?

(NASDAQ: HOTH) Hoth Therapeutics currently has 4,346,438 outstanding shares. With Hoth Therapeutics stock trading at $1.30 per share, the total value of Hoth Therapeutics stock (market capitalization) is $5.63M.

Hoth Therapeutics stock was originally listed at a price of $213.25 in Feb 15, 2019. If you had invested in Hoth Therapeutics stock at $213.25, your return over the last 5 years would have been -99.39%, for an annualized return of -63.97% (not including any dividends or dividend reinvestments).

How much is Hoth Therapeutics's stock price per share?

(NASDAQ: HOTH) Hoth Therapeutics stock price per share is $1.30 today (as of Feb 23, 2024).

What is Hoth Therapeutics's Market Cap?

(NASDAQ: HOTH) Hoth Therapeutics's market cap is $5.63M, as of Feb 24, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Hoth Therapeutics's market cap is calculated by multiplying HOTH's current stock price of $1.30 by HOTH's total outstanding shares of 4,346,438.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.